Evaluation of Pharmacokinetic Interactions After Oral Administration of Mycophenolate Mofetil and Valaciclovir or Aciclovir to Healthy Subjects

[1]  P. Ljungman,et al.  Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. , 2002, Blood.

[2]  A. Woodcock,et al.  Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  S. Gautam,et al.  Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. , 2002, Chest.

[4]  J. Wahlberg,et al.  CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  R. Chang,et al.  Prophylaxis of cytomegalovirus infection in renal transplantation. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  V. Armstrong,et al.  Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. , 2001, Clinical chemistry.

[7]  J. Dummer,et al.  Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis , 2001, Bone Marrow Transplantation.

[8]  J. Cailhier,et al.  CMV in kidney transplants in the tacrolimus-mycophenolate era. , 2001, Transplantation proceedings.

[9]  R. Stratta,et al.  Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. , 2001, Transplantation proceedings.

[10]  C. Legendre,et al.  VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATION , 2000, Transplantation.

[11]  Y. Le Meur,et al.  The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  V. Armstrong,et al.  Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. , 2000, Clinical chemistry.

[13]  V. Armstrong,et al.  Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. , 1999, Clinical chemistry.

[14]  V. Armstrong,et al.  Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil , 1999, British journal of pharmacology.

[15]  E. De Clercq,et al.  Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. , 1998, Antiviral research.

[16]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[17]  F. Aweeka,et al.  Pharmacokinetics of Mycophenolate Mofetil and Intravenous Ganciclovir Alone and in Combination in Renal Transplant Recipients , 1997, Pharmacotherapy.

[18]  S. Tadepalli,et al.  Scintillation proximity radioimmunoassay for the measurement of acyclovir. , 1996, Journal of pharmaceutical and biomedical analysis.

[19]  P. Rolan,et al.  Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans , 1995, Antimicrobial agents and chemotherapy.

[20]  D. Cederberg,et al.  Pharmacokinetics of the acyclovir pro‐drug valaciclovir after escalating single‐and multiple‐dose administration to normal volunteers , 1993, Clinical pharmacology and therapeutics.

[21]  F. Russel,et al.  Saturable Pharmacokinetics in the Renal Excretion of Drugs , 1989, Clinical pharmacokinetics.

[22]  P. de Miranda,et al.  Overview of acyclovir pharmacokinetic disposition in adults and children. , 1982, The American journal of medicine.